Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
long-term survivors
neutrophil-to-lymphocyte ratio
nivolumab
non-small cell lung cancer
overall survival
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
17
12
2021
received:
28
11
2021
accepted:
20
12
2021
pubmed:
7
1
2022
medline:
24
3
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
Nivolumab, an immune checkpoint inhibitor (ICI), has changed the treatment paradigm for advanced non-small cell lung cancer (NSCLC). However, factors associated with long-term survival in NSCLC patients treated with ICIs remain unknown. This study aimed to evaluate patient characteristics and clinical laboratory changes related to long-term survival in NSCLC patients treated with nivolumab, using real-world data. We retrospectively reviewed the medical records of consecutive patients with advanced NSCLC with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 treated with nivolumab. We defined patients with overall survival (OS) ≥3 years as long-term survivors. We evaluated the differences in patient characteristics and tumor response between nonlong-term survivors and long-term survivors and performed univariate and multivariate analyses of factors associated with long-term survival. Out of 213 patients with advanced NSCLC treated with nivolumab, 162 patients with ECOG-PS ≤1 were included in the study. Young age, ECOG-PS 0, absolute neutrophil count decrease, lymphocyte percentage increase, and neutrophil-to-lymphocyte ratio (NLR) change (ΔNLR) <1 were significantly associated with long-term survival. Long-term survivors had significantly higher response and disease control rates than nonlong-term survivors. Multivariate analysis showed that ΔNLR <1 was significantly associated with long-term survival. Further, OS was significantly different between the PS 0 and PS 1 groups (median OS: 32.0 months vs. 10.6 months) and the nonincreasing NLR and increasing NLR groups (median OS: 20.8 months vs. 5.7 months). ΔNLR <1 was a significant long-term survival factor compared to ΔNLR ≥1 in advanced NSCLC patients treated with nivolumab.
Sections du résumé
BACKGROUND
Nivolumab, an immune checkpoint inhibitor (ICI), has changed the treatment paradigm for advanced non-small cell lung cancer (NSCLC). However, factors associated with long-term survival in NSCLC patients treated with ICIs remain unknown. This study aimed to evaluate patient characteristics and clinical laboratory changes related to long-term survival in NSCLC patients treated with nivolumab, using real-world data.
METHODS
We retrospectively reviewed the medical records of consecutive patients with advanced NSCLC with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 treated with nivolumab. We defined patients with overall survival (OS) ≥3 years as long-term survivors. We evaluated the differences in patient characteristics and tumor response between nonlong-term survivors and long-term survivors and performed univariate and multivariate analyses of factors associated with long-term survival.
RESULTS
Out of 213 patients with advanced NSCLC treated with nivolumab, 162 patients with ECOG-PS ≤1 were included in the study. Young age, ECOG-PS 0, absolute neutrophil count decrease, lymphocyte percentage increase, and neutrophil-to-lymphocyte ratio (NLR) change (ΔNLR) <1 were significantly associated with long-term survival. Long-term survivors had significantly higher response and disease control rates than nonlong-term survivors. Multivariate analysis showed that ΔNLR <1 was significantly associated with long-term survival. Further, OS was significantly different between the PS 0 and PS 1 groups (median OS: 32.0 months vs. 10.6 months) and the nonincreasing NLR and increasing NLR groups (median OS: 20.8 months vs. 5.7 months).
CONCLUSIONS
ΔNLR <1 was a significant long-term survival factor compared to ΔNLR ≥1 in advanced NSCLC patients treated with nivolumab.
Identifiants
pubmed: 34989133
doi: 10.1111/1759-7714.14303
pmc: PMC8841702
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
593-601Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Thorac Cancer. 2021 Mar;12(5):613-618
pubmed: 33448648
Transl Lung Cancer Res. 2019 Aug;8(4):413-428
pubmed: 31555516
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Thorac Cancer. 2018 Oct;9(10):1291-1299
pubmed: 30126063
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
JAMA Netw Open. 2021 Feb 1;4(2):e2037120
pubmed: 33570575
JAMA Oncol. 2018 Apr 1;4(4):522-528
pubmed: 29470579
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Eur J Cancer. 2020 Mar;128:17-26
pubmed: 32109847
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Transpl Int. 2009 Nov;22(11):1041-50
pubmed: 19624493
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Lung Cancer. 2021 Aug;158:97-106
pubmed: 34144405
Arch Gerontol Geriatr. 1994 Sep-Oct;19(2):171-83
pubmed: 15374283
J Thorac Oncol. 2016 Nov;11(11):1927-1939
pubmed: 27496650
BMC Cancer. 2021 Apr 21;21(1):441
pubmed: 33882890
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Thorac Dis. 2021 May;13(5):2824-2832
pubmed: 34164174
J Clin Oncol. 2021 Mar 1;39(7):723-733
pubmed: 33449799
Cancer Chemother Pharmacol. 2020 Apr;85(4):761-771
pubmed: 32193618
Cancer Immunol Immunother. 2018 Mar;67(3):459-470
pubmed: 29204702
Eur J Cancer. 2019 Dec;123:72-80
pubmed: 31671314
Invest New Drugs. 2019 Dec;37(6):1257-1265
pubmed: 30937690
Thorac Cancer. 2022 Feb;13(4):593-601
pubmed: 34989133
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32503948
J Thorac Oncol. 2018 Jan;13(1):97-105
pubmed: 29170120
Onco Targets Ther. 2021 Mar 17;14:1961-1968
pubmed: 33762828